Paediatric clinical trials bring unique safety challenges. Unlike adult studies, adverse event assessment often depends entirely on caregiver observations, making data quality, medical oversight, and safety signal interpretation significantly more complex. In gastrointestinal studies involving infants and young children, distinguishing normal developmental variability from potential product related events requires specialized expertise and a highly structured safety framework.
In this case study, we share how AWINSA Life Sciences supported a large multinational paediatric GI clinical trial through an integrated approach combining pharmacovigilance, medical monitoring, regulatory compliance, signal detection, and caregiver reported outcome management. The result was a robust safety program that ensured data integrity, regulatory compliance, and patient safety throughout the study.
At AWINSA Life Sciences, we partner with sponsors across the full product lifecycle, delivering tailored pharmacovigilance and clinical safety solutions that help advance innovative therapies while keeping patient safety at the forefront.
Copyright © 2024 AWINSA Life Sciences Pvt. Ltd. All rights reserved.
59 E,Shrewsbury Place
Princeton, NJ 08540
United States
E13/9 First floor, Vasant Vihar,
New Delhi 110057
Wilhelmina Druckerlaan 10,
6532 SR,
Nijmegen,
The Netherlands
Cerrada Ahuizotla 53,
Col. Santiago Ahuizotla,
Del. Azcapotzalco
CP.02750
Ciudad de México, México.
